WestPark Capital analyst Curtis Shauger initiated coverage on Alphabet (NASDAQ:GOOG) on Tuesday with a Buy rating and a price ...

Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ...

Despite the drop, Blackledge is still very bullish on Alphabet, and he left his buy recommendation intact. And why shouldn't he? Even at that reduced price target, the anticipated upside is over 30% ...

We recently published a list of Top 10 Stocks to Buy According to Two Sigma Investments. In this article, we are going to ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...

The drug discovery company, which has partnerships with Eli Lilly and Novartis, is developing AI models to design drugs and ...

Thanks to artificial intelligence, DeepSeek’s founder, Alphabet’s CEO, four CoreWeave execs and a bunch of other tech tycoons ...

Alphabet has been treading water for the past six months, recording a small return of 2.2% while holding steady at $165.80.

15.2%, given Alphabet's status as a free cash flow machine. This is why we reiterate our estimates for FY25 diluted EPS at $9.12, FY26 at $10.64, FY27 at $12.48, and FY28 at $14.13. Thus ...

Alphabet, Oracle, ServiceNow, Salesforce, and UnitedHealth Group are the five Healthcare stocks to watch today, according to ...